A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale

PHASE4CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

September 7, 2020

Study Completion Date

September 29, 2020

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium + olodaterol

Oral Inhalation

DRUG

Placebo

Oral Inhalation

Trial Locations (26)

10455

CHEAR Center LLC, The Bronx

10787

Klinische Forschung Berlin GbR, Berlin

20354

Hamburger Institut für Therapieforschung GmbH (HIT), Hamburg

22927

Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf

23552

KLB Gesundheitsforschung Lübeck GmbH, Lübeck

27103

Southeastern Research Center, Winston-Salem

27607

North Carolina Clinical Research, Raleigh

29303

Vitalink Research - Spartansburg, Spartanburg

29325

Carolina Medical Research, Clinton

29340

VitaLink Research -Gaffney, Gaffney

29406

Lowcountry Lung and Critical Care, Charleston

33511

Meris Clinical Research, Brandon

33606

Clinical Research of West Florida, Inc., Tampa

33765

Clinical Research of West Florida, Inc., Clearwater

34746

Clinical Research Specialists LLC, Kissimmee

35501

Jasper Summit Research, LLC, Jasper

36420

SEC Lung, Andalusia

45231

Bernstein Clinical Rsrch Ctr, Cincinnati

48152

Pulmonary Rsrch Inst of SE MI, Farmington Hills

55125

Minnesota Lung Center, Woodbury

55435

Minnesota Lung Center and Sleep Institute, Edina

60596

IKF Pneumologie GmbH & Co. KG, Frankfurt

70115

Best Clinical Trials, LLC, New Orleans

78229

Diagnostics Research Group, San Antonio

02747

Infinity Medical Research, North Dartmouth

03743

Valley Regional Hospital, Claremont

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY